463 patents
Page 17 of 24
Utility
Isolated human cell with an inactivated glucocorticoid receptor gene
2 Feb 21
Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR.
Andreas Reik, Michael Jensen, Michael C. Holmes, Philip D. Gregory, Dale Ando
Filed: 20 Nov 15
Utility
Triptolide Antibody Conjugates
28 Jan 21
The antibody-drug conjugates provided herein including embodiments thereof, include the compound triptolide attached to a cancer-specific antibody (e.g., cetuximab) and are, inter alia, useful as highly effective anti-cancer therapeutics.
Dan Raz, David Horne, Keqiang Zhang, Yuelong Ma
Filed: 23 Jul 20
Utility
Self-directed Method for Cell-type Identification and Separation of Gene Expression Microarrays
28 Jan 21
Gene expression analysis is generally performed on heterogeneous tissue samples consisting of multiple cell types.
Neta Zuckerman, Yair Noam, Andrea Goldsmith, Peter P. Lee
Filed: 15 Jul 20
Utility
Modified Tracrrnas Grnas, and Uses Thereof
21 Jan 21
Provided are compositions and methods for altering gene expression in cells.
Kevin V. MORRIS, Tristan SCOTT
Filed: 17 Dec 18
Utility
Promoting and Protecting Functional Beta Cell Mass by Syntaxin 4 Enrichment
30 Dec 20
Disclosed are Syntaxin 4-overexpressing pancreatic islet β-cells, methods of making these cells, and methods of using these cells for promoting and protecting functional β-cell mass, thereby to treat and/or prevent various insulin-related diseases and conditions including diabetes and pre-diabetes.
Debbie C. THURMOND
Filed: 7 Feb 19
Utility
Recombinant Adeno-associated Vectors for Targeted Treatment
30 Dec 20
Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided.
Saswati Chatterjee, Laura Jane Smith, Kamehameha Wong
Filed: 10 Feb 20
Utility
DOC2B As a Biomarker for Type 1 Diabetes
30 Dec 20
Disclosed is the use of DOC2B as an early stage biomarker for diagnosing type 1 diabetes (T1D) or pre-T1D or for assessing the risk of T1D or pre-T1D.
Debbie C. THURMOND
Filed: 7 Feb 19
Utility
Compounds of Chemically Modified Oligonucleotides and Methods of Use Thereof
30 Dec 20
The present disclosure relates to isolated compounds including a nucleic acid sequence capable of hybridizing to an RNA sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microRNA-379 transcript; method of treating diabetic nephropathy in a subject with the compounds; and method of inhibiting expression of a mammalian microRNA-379 megacluster with the compounds.
Rama Natarajan, Mitsuo Kato
Filed: 4 Aug 20
Utility
P38 Map Kinase Inhibitors
23 Dec 20
Provided herein, inter alia, are p38 mitogen-activated protein kinase inhibitors and methods of treating cancer using p38 mitogen-activated protein kinase inhibitors
John J. Rossi, Sorah Yoon
Filed: 14 Jun 20
Utility
Chemically Encoded Spatially Addressed Library Screening Platforms
2 Dec 20
Provided herein are encoded split pool libraries useful, inter alia, for forming highly diverse and dense arrays for screening and detection of a variety of molecules.
Jacob BERLIN, Gregory COPELAND, Kathleen ELISON, Hurik MURADYAN
Filed: 27 Jul 20
Utility
Multi-modal Image-guided Radiation System
2 Dec 20
Systems and methods relate to multi-modal imaging of tissue combined with highly focused radiation interventions.
Susanta K. Hui, Gultekin Gulsen
Filed: 27 May 20
Utility
Chemically Encoded Spatially Addressed Library Screening Platforms
2 Dec 20
Provided herein are encoded split pool libraries useful, inter alia, for forming highly diverse and dense arrays for screening and detection of a variety of molecules.
Jacob Berlin, Gregory Copeland, Kathleen Elison, Hurik Muradyan
Filed: 29 Jul 20
Utility
CTLA-4 Aptamer Conjugates
2 Dec 20
Provided herein are, inter alfa, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells.
Hua YU, Andreas HERRMANN, Marcin Tomasz KORTYLEWSKI
Filed: 3 Jun 20
Utility
Detecting Cytokine Signaling Responsiveness In Immune Cells
2 Dec 20
Provided herein are methods of detecting cytokine signaling responsiveness in immune cells from a cancer subject and determining risk of relapse of cancer in a subject.
Peter P. LEE, Lei WANG
Filed: 31 May 20
Utility
Methods of treating pancreatic cancer using GPCR antagonists
30 Nov 20
Provided herein are, inter alia, compositions and methods for the treatment of cancer and inhibition of metastasis.
Tijana Talisman, Sunetra Biswas
Filed: 27 Sep 17
Utility
Cysteine Peptide-enabled Antibodies
25 Nov 20
Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments covalently linked to a peptide compound through a disulfide linkage.
John C. Williams, Krzysztof Bzymek, Yuelong Ma, David Horne, Jeremy King
Filed: 5 Dec 17
Utility
Nir-conjugated Tumor-specific Antibodies and Uses Thereof
25 Nov 20
Disclosed is a tumor-specific antibody and fluorophore conjugate for detecting, localizing and imaging of various tumors.
Paul YAZAKI, Jack SHIVELY, Michael BOUVET, Jonathan DELONG, Yuman FONG
Filed: 13 Aug 20
Utility
MVA vaccine for delivery of a UL128 complex and preventing CMV infection
23 Nov 20
In one embodiment, an expression system for expressing a UL128 complex is provided herein.
Don J. Diamond, Felix Wussow
Filed: 11 Aug 19
Utility
Methods of Quantifying Methylglyoxal-induced Nucleic Acid Adducts
18 Nov 20
Methods of quantifying a N2-(1-carboxyethyl)-2′-deoxyguanosine (CEdG) and N2-(1-carboxyethyl)-guanosine (CEG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer.
Samuel RAHBAR, Timothy W. SYNOLD, John TERMINI, Sarah SHUCK
Filed: 30 Jul 20
Utility
Microwave Coaptive Surgical Sealing Tool
18 Nov 20
A coaptive surgical sealing tool may be similar to an ordinary hemostat with long (50, 60, 70 or 80 mm) thin jaws for sliding into the liver parenchyma, without tearing the larger blood vessels.
Gagandeep Singh
Filed: 31 May 20